Literature DB >> 1770836

Dystrophin and disease.

E P Hoffman1, L Schwartz.   

Abstract

Recent advances concerning the genetic and biochemical basis of Duchenne and Becker muscular dystrophies have resulted in a good understanding of the etiology of these common dystrophies. An important secondary consequence of the genetic and biochemical research has been the generation of gene-based and protein-based diagnostic tools which enable a 'molecular diagnosis' for patients and their families. This review summarizes our current understanding of the genetics, biochemistry, and pathophysiology of Duchenne dystrophy, and gives an overview of the molecular diagnostic tools and their applications. Recent correlations of clinical, genetic and biochemical data have indicated that dystrophinopathies can present with a wide range of neuromuscular symptoms, and that neither male sex nor proximal weakness are diagnostic prerequisites for consideration of an underlying dystrophin abnormality.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1770836     DOI: 10.1016/0098-2997(91)90001-3

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN: 0098-2997


  8 in total

1.  Rapamycin ameliorates dystrophic phenotype in mdx mouse skeletal muscle.

Authors:  Saman Eghtesad; Siddharth Jhunjhunwala; Steven R Little; Paula R Clemens
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

2.  Long-term treatment with naproxcinod significantly improves skeletal and cardiac disease phenotype in the mdx mouse model of dystrophy.

Authors:  Kitipong Uaesoontrachoon; James L Quinn; Kathleen S Tatem; Jack H Van Der Meulen; Qing Yu; Aditi Phadke; Brittany K Miller; Heather Gordish-Dressman; Ennio Ongini; Daniela Miglietta; Kanneboyina Nagaraju
Journal:  Hum Mol Genet       Date:  2014-01-23       Impact factor: 6.150

3.  Modulation by prednisolone of calcium handling in skeletal muscle cells.

Authors:  L Metzinger; A C Passaquin; W J Leijendekker; P Poindron; U T Rüegg
Journal:  Br J Pharmacol       Date:  1995-12       Impact factor: 8.739

4.  Fluorescent multiplex linkage analysis and carrier detection for Duchenne/Becker muscular dystrophy.

Authors:  L S Schwartz; J Tarleton; B Popovich; W K Seltzer; E P Hoffman
Journal:  Am J Hum Genet       Date:  1992-10       Impact factor: 11.025

5.  Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology.

Authors:  Y W Chen; P Zhao; R Borup; E P Hoffman
Journal:  J Cell Biol       Date:  2000-12-11       Impact factor: 10.539

6.  Ryanodine channel complex stabilizer compound S48168/ARM210 as a disease modifier in dystrophin-deficient mdx mice: proof-of-concept study and independent validation of efficacy.

Authors:  Roberta Francesca Capogrosso; Paola Mantuano; Kitipong Uaesoontrachoon; Anna Cozzoli; Arcangela Giustino; Todd Dow; Sadish Srinivassane; Marina Filipovic; Christina Bell; Jack Vandermeulen; Ada Maria Massari; Michela De Bellis; Elena Conte; Sabata Pierno; Giulia Maria Camerino; Antonella Liantonio; Kanneboyina Nagaraju; Annamaria De Luca
Journal:  FASEB J       Date:  2018-01-03       Impact factor: 5.834

7.  Effect of rapamycin on immunity induced by vector-mediated dystrophin expression in mdx skeletal muscle.

Authors:  Saman Eghtesad; Siddharth Jhunjhunwala; Steven R Little; Paula R Clemens
Journal:  Sci Rep       Date:  2012-05-08       Impact factor: 4.379

8.  Elusive sources of variability of dystrophin rescue by exon skipping.

Authors:  Maria Candida Vila; Margaret Benny Klimek; James S Novak; Sree Rayavarapu; Kitipong Uaesoontrachoon; Jessica F Boehler; Alyson A Fiorillo; Marshall W Hogarth; Aiping Zhang; Conner Shaughnessy; Heather Gordish-Dressman; Umar Burki; Volker Straub; Qi Long Lu; Terence A Partridge; Kristy J Brown; Yetrib Hathout; John van den Anker; Eric P Hoffman; Kanneboyina Nagaraju
Journal:  Skelet Muscle       Date:  2015-12-01       Impact factor: 4.912

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.